Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes

被引:17
作者
Kato, Masaki [1 ,2 ]
Hamada-Tsutsumi, Susumu [3 ,4 ]
Okuse, Chiaki [5 ]
Sakai, Aiko [6 ]
Matsumoto, Nobuyuki [2 ]
Sato, Masaaki [7 ]
Sato, Toshiyuki [7 ]
Arito, Mitsumi [7 ]
Omoteyama, Kazuki [7 ]
Suematsu, Naoya [7 ]
Okamoto, Kazuki [7 ]
Kato, Takanobu [8 ]
Itoh, Fumio [2 ]
Sumazaki, Ryo [6 ]
Tanaka, Yasuhito [3 ,4 ]
Yotsuyanagi, Hiroshi [9 ]
Kato, Tomohiro [7 ]
Kurokawa, Manae Suzuki [1 ]
机构
[1] St Marianna Univ, Dis Biomarker Anal & Mol Regulat, Grad Sch Med, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan
[2] St Marianna Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Sch Med, Kawasaki, Kanagawa, Japan
[3] Nagoya City Univ, Dept Virol, Grad Sch Med Sci, Nagoya, Aichi, Japan
[4] Nagoya City Univ, Liver Unit, Grad Sch Med Sci, Nagoya, Aichi, Japan
[5] Kawasaki Municipal Tama Hosp, Div Gastroenterol & Hepatol, Kawasaki, Kanagawa, Japan
[6] Univ Tsukuba, Dept Child Hlth, Fac Med, Tsukuba, Ibaraki, Japan
[7] St Marianna Univ, Clin Prote & Mol Med, Grad Sch Med, Kawasaki, Kanagawa, Japan
[8] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan
[9] Univ Tokyo, Grad Sch Med, Dept Infect Dis, Tokyo, Japan
关键词
Hepatitis B virus; Genotypes; Universal vaccination; Polyclonal anti-HBs antibodies; HEPATITIS-B-VIRUS; SURFACE-ANTIGEN; TRANSMISSION; CHILDREN; JAPAN; PERSISTENCE;
D O I
10.1007/s00535-017-1316-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background In universal hepatitis B (HB) vaccination, single vaccine-derived polyclonal anti-HBs antibodies (anti-HBs) need to inhibit infection of HB viruses (HBV) of non-vaccine genotypes. We experimentally addressed this issue. Methods Anti-HBs-positive sera were obtained by vaccination with genotype A- or C-derived HBs antigen (HBsAg, gtA-sera or gtC-sera). Their reactivity to genotype A- and C-derived HBsAg (gtA-Ag and gtC-Ag) was measured by ELISA. The capacity of sera to neutralize HBV was evaluated using an in vitro infection model. Results Of 135 anti-gtA-Ag-reactive gtA-sera, 134 (99.3%) were anti-gtC-Ag-reactive. All (100%) 120 anti-gtC-Ag-reactive gtC-sera were anti-gtA-Ag-reactive. The reactivity to gtA-Ag was strongly correlated with that to gtC-Ag (gtA-sera, rho = 0.989; gtC-sera, rho = 0.953; p < 0.01). In gtA-sera (n = 10), anti-HBs to gtA-Ag were less completely absorbed with gtC-Ag (96.4%) than with gtA-Ag (100%, p < 0.05). Similarly, in gtC-sera (n = 10), anti-HBs to gtC-Ag were less completely absorbed with gtA-Ag (96.0%) than with gtC-Ag (100%, p < 0.01). Thus, 3.6 and 4.0% of anti-HBs in gtA-sera and gtC-sera were vaccine genotype HBsAg-specific, respectively. In the neutralization test, gtA-sera (n = 4) and gtC-sera (n = 3) with anti-HBs titers adjusted to 100 mIU/mL equally inhibited genotype C HBV infection (92.8 vs. 95.4%, p = 0.44). However, at 30 mIU/mL, the gtA-sera less effectively inhibited infection than the gtC-sera (60.2 vs. 90.2%, p < 0.05). Conclusion Vaccination with genotype A- or C-derived HBsAg provided polyclonal anti-HBs that sufficiently bound to non-vaccine genotype HBsAg. However, a small portion of anti-HBs were specific to the vaccine genotype HBsAg. High anti-HBs titers would be required to prevent HBV infection of non-vaccine genotypes. UMIN/CTR UMIN000014363.
引用
收藏
页码:1051 / 1063
页数:13
相关论文
共 36 条
[1]  
[Anonymous], 2016, HEP B
[2]   Amino acid substitutions in the S region of hepatitis B virus in sera from patients with acute hepatitis [J].
Aono, Junko ;
Yotsuyanagi, Hiroshi ;
Miyoshi, Hideyuki ;
Tsutsumi, Takeya ;
Fujie, Hajime ;
Shintani, Yoshizumi ;
Moriya, Kyoji ;
Okuse, Chiaki ;
Suzuki, Michihiro ;
Yasuda, Kiyomi ;
Iino, Shiro ;
Koike, Kazuhiko .
HEPATOLOGY RESEARCH, 2007, 37 (09) :731-739
[3]   Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan [J].
Avazova, Dildora ;
Kurbanov, Fuat ;
Tanaka, Yasuhito ;
Sugiyama, Masaya ;
Radchenko, Ivan ;
Ruziev, Dilmurod ;
Musabaev, Erkin ;
Mizokami, Masashi .
JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (02) :217-224
[4]  
Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6
[5]  
Cassidy A, 2011, EXPERT REV VACCINES, V10, P1709, DOI [10.1586/ERV.11.151, 10.1586/erv.11.151]
[6]   Persistence of long-term immunity to hepatitis B among adolescents immunized at birth [J].
Chaves, Sandra S. ;
Fischer, Gayle ;
Groeger, Justina ;
Patel, Priti R. ;
Thompson, Nicola D. ;
Teshale, Eyasu H. ;
Stevenson, Kuartei ;
Yano, Victor M. ;
Armstrong, Gregory L. ;
Samandari, Taraz ;
Kamili, Saleem ;
Drobeniuc, Jan ;
Hu, Dale J. .
VACCINE, 2012, 30 (09) :1644-1649
[7]   Seroepidemiology of hepatitis B virus infection in children - Ten years of mass vaccination in Taiwan [J].
Chen, HL ;
Chang, MH ;
Ni, YH ;
Hsu, HY ;
Lee, PI ;
Lee, CY ;
Chen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (11) :906-908
[8]   Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization [J].
Chongsrisawat, Voranush ;
Yoocharoen, Pornsak ;
Theamboonlers, Apiradee ;
Tharmaphornpilas, Piyanit ;
Warinsathien, Porpit ;
Sinlaparatsamee, Supakarn ;
Paupunwatana, Siriraj ;
Chaiear, Kasemporn ;
Khwanjaipanich, Sawan ;
Poovorawan, Yong .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2006, 11 (10) :1496-1502
[9]   Selective Hepatitis B Virus Vaccination Has Reduced Hepatitis B Virus Transmission in The Netherlands [J].
Hahne, Susan ;
van Houdt, Robin ;
Koedijk, Femke ;
van Ballegooijen, Marijn ;
Cremer, Jeroen ;
Bruisten, Sylvia ;
Coutinho, Roel ;
Boot, Hein .
PLOS ONE, 2013, 8 (07)
[10]   Validation of Cross-Genotype Neutralization by Hepatitis B Virus-Specific Monoclonal Antibodies by In Vitro and In Vivo Infection [J].
Hamada-Tsutsumi, Susumu ;
Iio, Etsuko ;
Watanabe, Tsunamasa ;
Murakami, Shuko ;
Isogawa, Masanori ;
Iijima, Sayuki ;
Inoue, Takako ;
Matsunami, Kayoko ;
Tajiri, Kazuto ;
Ozawa, Tatsuhiko ;
Kishi, Hiroyuki ;
Muraguchi, Atsushi ;
Joh, Takashi ;
Tanaka, Yasuhito .
PLOS ONE, 2015, 10 (02)